TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06855277: A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer

Sponsor: Novartis Pharmaceuticals · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 940 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$3,936,240

Rescue Site Savings

+$2,624,160

Unlock Full NCT06855277 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06855277 Rescue Dossier →